Monday, December 23, 2024
HomeTagsPFS

PFS

Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial

Positive high-level results from the TROPION-Lung01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the dual primary endpoint of...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics